- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
- Combination Product · Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–41
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pancreatic Cancer
- Interventions
- Whole liver irradiation (WLI), Gemcitabine and Cisplatin
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Rucaparib, Placebo
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
- Conditions
- Solid Tumor, Adult
- Interventions
- Pembrolizumab 200 mg Q3W
- Drug
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
- Interventions
- CB-839, Talazoparib
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
- Interventions
- Rucaparib
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 6
- States / cities
- San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
- Interventions
- NUV-868, Olaparib, Enzalutamide
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- Advanced Cancers
- Interventions
- LY2606368
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
- Interventions
- Carboplatin, Olaparib
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 18
- States / cities
- West Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)
- Interventions
- Pamiparib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Athens, Georgia • The Bronx, New York • Seattle, Washington
- Conditions
- ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Other · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1151
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
- Conditions
- Solid Tumor, Adult, Homologous Recombination Deficiency
- Interventions
- Niraparib, Carboplatin
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Hackensack, New Jersey + 1 more
- Conditions
- Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
- Interventions
- Lorigerlimab
- Drug
- Lead sponsor
- Peter Hosein, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Ovarian Cancer
- Interventions
- Tuvusertib (M1774), Niraparib, Lartesertib (M4076)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 4 more
- Conditions
- Ovarian Cancer
- Interventions
- AZD2281, matching placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 11
- States / cities
- Berkeley, California • San Francisco, California • West Hollywood, California + 6 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
- Interventions
- Olaparib
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Cisplatin, Paclitaxel
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 16 more